Jan 30, 2025
Kathy Lee-Sepsick, President, Founder, and CEO of Femasys, uses innovative medical technologies to address unmet women's reproductive healthcare needs. Femasyis is developing treatments for infertility and birth control and diagnostic tools to support its treatment offerings. The devices are intentionally designed to be more accessible, less invasive, and safer for women than existing options, some of which have not changed in 100 years.
Kathy explains, "Our technologies are just for women. So, we include broad categories of women. And we did this, particularly with the FemBloc product that we're advancing. It's a non-surgical permanent birth control solution for women that is delivered in the office. No anesthesia, no incisions, no hormones, no implants, none of the things that come par for the course for what's out there right now. And we included in our patient population women who did not have children before, which had never been done before."
"So, there've been other technologies that have come and have failed in this market in an attempt to bring forward a permanent birth control solution that's non-surgical. And they only included women who have had children. When you include women who haven't had children, you have to be very responsible to do that because women should have a choice no matter what their choice is as far as childbearing."
"When we think about infertility, it's not just a woman’s issue. And we're seeing the problems in donor sperm also, whether it's a single person or the LGTQ community that's coming forward, they have to get the sperm to contribute to the overall process. And the sperms compromised, like I said, even with donors. So we see a third of the time that it's strictly the male issue. About a third of the time, it's a female issue only, and then the combination is both. So about 50% of the time the male factor is contributing."
#Femasys $FEMY #WomensHealth #IVF #Fertility #Birthcontrol #FemaSeed #FemBloc #FemVue #FemCerv
